



**Limited Review Report on Quarterly Financial Results of INDRAYANI BIOTECH LIMITED pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**Review Report to the Board of Directors,  
INDRAYANI BIOTECH LIMITED**

We have reviewed the accompanying statement of unaudited standalone financial results of **INDRAYANI BIOTECH LIMITED** ('the Company') for the quarter ended June 30 2019. This statement, is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the applicable Indian Accounting Standards (Ind AS) specified under Section 133 of the Companies Act, 2013. Our Responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatements. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Venkatesh & Co  
Chartered Accountants  
F.R.No.004636S**

**CA Dasaraty V  
Partner  
M.No.026336**



**Place : Chennai  
Date : 10<sup>th</sup> August 2019,  
UDIN : 19026336AAAABW8893**



# Indrayani Biotech Limited

Reg. Office: 41(23) "RAMA NIVAS",  
 Parameswari Nagar I Street, Adyar, Chennai - 600 020.  
 Phone : +91 044 - 2446 3751  
 Email : indrayanichennai@gmail.com  
 Website: www.indrayani.com

INDRAYANI BIOTECH LIMITED					
No 41 (23) RAMA NIVAS , Parameswari Nagar , 1st Street, Adayar , Chennai 600 020					
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th June 2019					
Rs. In Lakhs					
PARTICULARS		QUARTER ENDED			
Sr No	PARTICULARS	3 months ended 30/06/2019	Corresponding 3 months ended in the previous year 30/06/2018	Year to date figures for current period ended 30/06/2019	Previous Year ended 31/03/2019
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
A	Date of start of reporting period	4/1/2019	4/1/2018	4/1/2019	4/1/2018
B	Date of end of reporting period	6/30/2019	6/30/2018	6/30/2019	3/31/2019
C	Whether results are audited or unaudited	Unaudited	Unaudited	Unaudited	UnAudited
D	Nature of report standalone or consolidated	Standalone	Standalone	Standalone	Standalone
<b>1</b>	<b>Income from Operations</b>				
	(a) Net Sales/Revenue from Operations	-	-	-	
	(b) Other Income	-	-	-	16.110
	<b>Total Income from Operations</b>	-	-	-	<b>16.110</b>
<b>2</b>	<b>Expenses</b>				
	(a) Cost of Materials consumed	-	-	-	
	(b) Purchase of stock-in-trade	-	-	-	
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	
	(d) Employee benefits expenses	-	0.600	-	3.300
	(e) Finance Costs	1.247	0.006	1.247	0.010
	(f) Depreciation and amortisation expense	-	-	-	
	(g) Other expenses				
	- Advertisement	0.042	0.226	0.042	1.991
	- Audit Fees	-	-	-	1.500
	- Business Promotion	-	-	-	0.020
	- Legal & Professional Expenses	1.555	0.384	1.555	13.023
	- Rates & Taxes	3.540	0.025	3.540	0.030
	- Telephone & Postage	-	-	-	
	- Travelling & Conveyance	0.793	-	0.793	0.634
	- Filing Fees & Subscription	-	0.213	-	0.210
	- Printing & Stationery	-	-	-	0.500
	- Postage & Courier	-	-	-	0.010
	- Interest and Finance charges	0.003	0.003	-	
	- Prior Period Expenses	-	-	-	
	Total Other expenses	5.932	0.850	5.930	18.180
	<b>Total Expenses</b>	<b>7.179</b>	<b>1.456</b>	<b>7.177</b>	<b>21.490</b>


K. Srinivasan



## Indrayani Biotech Limited

Reg. Office: 41(23) "RAMA NIVAS",  
Parameswari Nagar I Street, Adyar, Chennai - 600 020.  
Phone : +91 044 - 2446 3751  
Email : indrayanichennai@gmail.com  
Website: www.indrayani.com

3	<b>Total profit / (Loss) before exceptional items and tax</b>	(7.179)	(1.456)	(7.177)	(5.380)
4	Exceptional Items				
5	<b>Total profit / (Loss) before tax</b>	(7.179)	(1.456)	(7.177)	(12.030)
7	<b>Tax Expenses</b>				
8	Current Tax	-	-	-	
9	Deferred Tax	-	-	-	
10	<b>Total Tax Expenses</b>	-	-	-	
	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	-	-	-	
11	<b>Net Profit Loss for the period from continuing operations</b>	(7.179)	(1.456)	(7.177)	(12.030)
15	<b>Profit (loss) from discontinued operations before tax</b>	-	-	-	
16	<b>Tax expense of discontinued operations</b>	-	-	-	
	<b>Net profit (loss) from discontinued operation after tax</b>	-	-	-	
19	<b>Share of profit (loss) of associates and joint ventures accounted for using equity method</b>	-	-	-	
21	<b>Total profit (loss) for period</b>	(7.179)	(1.456)	(7.177)	(12.030)
22	<b>Other comprehensive income net of taxes</b>	-	-	-	
23	<b>Total Comprehensive Income for the period</b>	-	-	-	
24	<b>Total profit or loss, attributable to</b>				
	Profit or loss, attributable to owners of parent	(7.179)	(1.456)	(7.177)	(12.030)
	Total profit or loss, attributable to non-controlling interests	-	-	-	
25	<b>Total Comprehensive income for the period attributable to</b>				
	Comprehensive income for the period attributable to owners of parent	-	-	-	-
	Total comprehensive income for the period attributable to owners of parent noncontrolling interests	-	-	-	-
26	<b>Details of equity share capital</b>				
	Paid-up equity share capital	364.386	364.386	364.386	364.386
	Face value of equity share capital	10.000	10.000	10.000	10.000
27	<b>Details of debt securities</b>				
	Paid-up debt capital	-	-	-	-
	Face value of debt securities	-	-	-	-
28	<b>Reserves excluding revaluation reserve</b>	-	-	-	-
29	<b>Debenture redemption reserve</b>	-	-	-	-



K. Anjan Reddy





## Indrayani Biotech Limited

Reg. Office: 41(23) "RAMA NIVAS",  
Parameswari Nagar I Street, Adyar, Chennai - 600 020.  
Phone : +91 044 - 2446 3751  
Email : indrayanichennai@gmail.com  
Website: www.indrayani.com

<b>30 Earnings per share</b>				
<b>i Earnings per equity share for continuing operations</b>				
Basic earnings (loss) per share from continuing operations	(0.197)	(0.040)	(0.197)	(0.330)
Diluted earnings (loss) per share from continuing operations	(0.197)	(0.040)	(0.197)	(0.330)
<b>ii Earnings per equity share for discontinued operations</b>				
Basic earnings (loss) per share from discontinued operations	-	-	-	-
Diluted earnings (loss) per share from discontinued operations	-	-	-	-
<b>iii Earnings per equity share</b>				
Basic earnings (loss) per share from continuing and discontinued operations	(0.040)	(0.120)	(0.197)	(0.340)
Diluted earnings (loss) per share from continuing and discontinued operations	(0.040)	(0.120)	(0.197)	(0.340)
<b>31 Debt equity ratio</b>				
<b>32 Debt service coverage ratio</b>				
<b>33 Interest service coverage ratio</b>				
<b>34 Disclosure of notes on financial results</b>				

### Notes:

1 The stand alone financial results are being forwarded to the Bombay Stock Exchanges (BSE & PSE)om)& also available on the company website (www.indrayani.c for uploading on the respective websites and are also available on the Company's website (www.indrayani.com).

2. The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors in the meeting held on 24-Jan-2019. The above financial results are subject to "Limited Review" by the Statutory Auditors of the Company.

3. The Company operates in a single business segment. Hence, no segment wise figures are published.

6. There were no investor complaints pending at the beginning or at the end of the quarter. No compliants were received during the quarter.

5. Previous period figures have been regrouped wherever necessary.

Date : 10/08/2019

Place : chennai

*K. Suresh Kumar*

